<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-150159" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dermatopathology, Cutaneous Lymphomas</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schukow</surname>
            <given-names>Casey</given-names>
          </name>
          <aff>ProMedica Monroe Regional Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmed</surname>
            <given-names>Aadil</given-names>
          </name>
          <aff>Rush University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Casey Schukow declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aadil Ahmed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-150159.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Primary cutaneous lymphomas are a heterogeneous group of T- and B-cell neoplastic entities impacting millions of individuals worldwide annually. In 2018, the World Health Organization updated the diagnostic criteria for the various subtypes of this group of tumors to assist dermatologists and pathologists in classifying them. Cutaneous B-cell lymphomas (CBCLs) are often distinguished clinically by their indolent behavior. Prominent dermal B cell infiltrates are often present, which is remarkable because B cell collections are not typically found in normal skin and are rarely observed in reactive conditions or other types of CL. The following activity outlines the evaluation of these tumors and highlights many pathologic underpinnings when managing patients with primary cutaneous lymphomas.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify all subtypes of cutaneous T- and B-cell lymphomas according to updated World Health Organization guidelines.</p></list-item><list-item><p>Summarize general histopathologic features of cutaneous T- and B-cell lymphomas.</p></list-item><list-item><p>Outline immunophenotypic and molecular findings of cutaneous lymphomas.</p></list-item><list-item><p>Review pertinent clinicopathologic findings associated with different cutaneous T- and B-cell lymphomas.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=150159&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=150159">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-150159.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary cutaneous lymphomas (CLs) are a heterogeneous group of skin-based non-Hodgkin lymphomas&#x000a0;lacking extracutaneous manifestations at the time of diagnosis and are the second most common form of extranodal lymphomas.<xref ref-type="bibr" rid="article-150159.r1">[1]</xref>&#x000a0;</p>
        <p>In 2018, the World Health Organization&#x02013;European Organization for Research and Treatment of Cancer (WHO-EORTC) published an updated classification of&#x000a0;CLs in the fourth edition of the WHO Classification of Skin Tumors Blue Book, which serves as the gold standard in the diagnosis.<xref ref-type="bibr" rid="article-150159.r2">[2]</xref>&#x000a0;CLs more frequently originate from a T-cell than a B-cell lineage.<xref ref-type="bibr" rid="article-150159.r3">[3]</xref>&#x000a0;In the Western world, cutaneous T-cell lymphomas (CTCLs) make up approximately 75% of all CL, with the majority&#x000a0;classified as&#x000a0;Mycosis fungoides (MF).<xref ref-type="bibr" rid="article-150159.r4">[4]</xref>&#x000a0;Around 6.4 per million persons worldwide are affected by CTCL, and the likelihood of the disease increases significantly with age.<xref ref-type="bibr" rid="article-150159.r5">[5]</xref>&#x000a0;The median age of diagnosis is approximately 54 years old,&#x000a0;although rarely, it may occur in children and adolescents.<xref ref-type="bibr" rid="article-150159.r6">[6]</xref><xref ref-type="bibr" rid="article-150159.r7">[7]</xref>&#x000a0;</p>
        <p>Patients with CTCL have increased risks of secondary cancers such as other non-Hodgkin lymphomas, melanoma, lung cancer, and bladder cancer.<xref ref-type="bibr" rid="article-150159.r8">[8]</xref>&#x000a0;When neoplastic MF cells are found in the blood, the condition is known as S&#x000e9;zary syndrome.<xref ref-type="bibr" rid="article-150159.r9">[9]</xref>&#x000a0;CLs are often complex and require clinical evaluation, light microscopic examination, immunohistochemistry analysis, and molecular work-up of skin biopsies.<xref ref-type="bibr" rid="article-150159.r10">[10]</xref></p>
        <p>Cutaneous B-cell lymphomas (CBCLs) are often distinguished clinically by their indolent behavior. Prominent dermal B cell infiltrates are often present, which is remarkable in that B cell collections are not typically&#x000a0;found&#x000a0;in normal skin and are rarely observed in reactive conditions or other types of CL.<xref ref-type="bibr" rid="article-150159.r11">[11]</xref>&#x000a0;See <bold>Image.</bold>&#x000a0;Dermal B-Cell Infiltrate (CBCL).</p>
        <p>A complete list of both CTCL and CBCL diagnoses according to the 2018 WHO-EORTC is listed below with respective abbreviations, which will be used throughout the rest of this chapter. Provisional diagnoses are included:<xref ref-type="bibr" rid="article-150159.r2">[2]</xref></p>
        <p><bold>Cutaneous T-cell Lymphoma </bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Mycosis fungoides (MF)</p>
          </list-item>
          <list-item>
            <p>MF variants
<list list-type="bullet"><list-item><p>Folliculotropic MF (FMF)</p></list-item><list-item><p>Pagetoid reticulosis (PR)</p></list-item><list-item><p>Granulomatous slack skin (GSS)/Granulomatous mycosis fungoides</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>S&#x000e9;zary syndrome (SS)</p>
          </list-item>
          <list-item>
            <p>Adult T-cell leukemia/lymphoma (ATL)</p>
          </list-item>
          <list-item>
            <p>Primary cutaneous CD30+ lymphoproliferative disorders
<list list-type="bullet"><list-item><p>Primary cutaneous anaplastic large cell lymphoma (C-ALCL)</p></list-item><list-item><p>Lymphomatoid papulosis (LyP)</p></list-item><list-item><p>Large cell transformation of mycosis fungoides</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)</p>
          </list-item>
          <list-item>
            <p>Extranodal natural killer (NK)-cell/T-cell lymphoma, nasal type</p>
          </list-item>
          <list-item>
            <p>Primary cutaneous peripheral T-cell lymphoma, rare subtypes
<list list-type="bullet"><list-item><p>Primary cutaneous gamma/delta T-cell lymphoma (PCGDTL)</p></list-item><list-item><p>Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (CD8+ AECTCL, provisional)</p></list-item><list-item><p>Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (CD4+SMT-LPD, provisional)</p></list-item><list-item><p>Primary cutaneous acral CD8+ T-cell lymphoma (provisional)</p></list-item><list-item><p>Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (NOS)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Cutaneous B-cell&#x000a0;Lymphoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary cutaneous marginal zone lymphoma (PCMZL)</p>
          </list-item>
          <list-item>
            <p>Primary cutaneous follicle center cell lymphoma (PCFCL)</p>
          </list-item>
          <list-item>
            <p>Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBLC, LT)</p>
          </list-item>
          <list-item>
            <p>EBV+ mucocutaneous ulcer (EBVMCU, provisional)</p>
          </list-item>
          <list-item>
            <p>Intravascular large B-cell lymphoma (IVBCL)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-150159.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>According to the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study published in 2020, patient characteristics associated with a significant&#x000a0;decrease in&#x000a0;quality of life (QoL) in MF/SS include newly diagnosed women and those with alopecia and confluent erythema.<xref ref-type="bibr" rid="article-150159.r12">[12]</xref>&#x000a0;</p>
        <p>In 2021, a published study of one-on-one patient interviews suggests that those with CTCL, such as MF, often report sleep interference, lack of understanding of their disease, feelings of uncertainty, depression, hopelessness, treatment/tumor burden, and sometimes suicidal thoughts.<xref ref-type="bibr" rid="article-150159.r13">[13]</xref>&#x000a0;Overall diminished health-related QoL occurs in both patients with CTCL and CBCL, especially those with advanced-stage disease, and this is well-reviewed in current literature.<xref ref-type="bibr" rid="article-150159.r14">[14]</xref></p>
      </sec>
      <sec id="article-150159.s4" sec-type="Causes">
        <title>Causes</title>
        <p>UV radiation is a risk factor for CTCL, given multiple studies supporting genetic evidence.<xref ref-type="bibr" rid="article-150159.r15">[15]</xref><xref ref-type="bibr" rid="article-150159.r16">[16]</xref><xref ref-type="bibr" rid="article-150159.r17">[17]</xref>&#x000a0;Except for adult T-cell leukemia/lymphoma (ATL), which is an aggressive peripheral T-cell lymphoma caused by the human T-lymphotropic virus type-1 (HTLV-1) and presents with skin findings in about half of cases,&#x000a0;epidemiologic studies have failed to identify or associate environmental or viral causes of most CTCL subtypes.<xref ref-type="bibr" rid="article-150159.r18">[18]</xref><xref ref-type="bibr" rid="article-150159.r19">[19]</xref>&#x000a0;However, certain medications, such as hydrochlorothiazide, may induce significant antigen-driven CTCL after chronic exposure (i.e., greater than one year).<xref ref-type="bibr" rid="article-150159.r20">[20]</xref><xref ref-type="bibr" rid="article-150159.r21">[21]</xref><xref ref-type="bibr" rid="article-150159.r20">[20]</xref>&#x000a0;</p>
        <p>As with most cases of CL/CTCL, the cause of CBCL is yet to be fully understood. However, chronic antigen stimulation is a potential etiology,<xref ref-type="bibr" rid="article-150159.r22">[22]</xref>&#x000a0;perhaps due to specific infectious agents like Borrelia burgdorferi,&#x000a0;Helicobacter pylori,&#x000a0;and Epstein-Barr virus.<xref ref-type="bibr" rid="article-150159.r23">[23]</xref><xref ref-type="bibr" rid="article-150159.r24">[24]</xref><xref ref-type="bibr" rid="article-150159.r25">[25]</xref><xref ref-type="bibr" rid="article-150159.r26">[26]</xref></p>
      </sec>
      <sec id="article-150159.s5" sec-type="Anatomical Pathology">
        <title>Anatomical Pathology</title>
        <p>Histology is vital in the diagnostic evaluation and work-up of cutaneous lymphoma, and unique growth patterns exist between CTCL and CBCL. The former often demonstrate atypical T-cell lymphocyte infiltration of the epidermis (epidermotropism), whereas the latter typically presents with dense dermal B-cell lymphocyte infiltrates (as&#x000a0;described above) without significant epidermal involvement.<xref ref-type="bibr" rid="article-150159.r11">[11]</xref><xref ref-type="bibr" rid="article-150159.r27">[27]</xref>&#x000a0;See <bold>Images.</bold>&#x000a0;Epidermotropism (CTLC), Dense B-Cell Dermal Infiltrate (CBCL).</p>
        <p>Six major anatomic/histologic patterns occur in CL: epidermotropic, nodular, diffuse, subcutaneous, angiocentric/angioinvasive, and intravascular. Epidermotropic infiltrates are commonly found in the initial stages of most CTCL (e.g., MF, patch, and plaque stage). In contrast, nodular and diffuse infiltrates are more common in later CTCL stages (e.g., MF, tumor stage) and CBCL. Subcutaneous growth suggests sub-dermal CL (e.g., SPTCL). Angiocentric/angioinvasive infiltrates are seen mainly in primary cutaneous gamma/delta and aggressive NK-cell/T-cell CLs but may also be present in less-aggressive CD30+ T-cell lymphoproliferative disorders (e.g., LyP, Type E). Intravascular growth, finally, can be seen in intravascular anaplastic large cell, large B-cell, NK-cell, or pseudolymphomas.<xref ref-type="bibr" rid="article-150159.r27">[27]</xref></p>
        <p>Because of overlapping histologic features and growth patterns, immunohistochemistry (IHC, or immunophenotyping) is necessary for further CL subtyping. Anatomic features with respective IHC for each 2018 WHO-EORTC subtype are summarized below:</p>
        <p>
<bold>Cutaneous T-cell&#x000a0;Lymphoma</bold>
</p>
        <p>MF/SS: Band-like papillary dermal infiltrate with epidermotropism (patch stage) and formation of Pautrier's microabscesses (collection of atypical lymphocytes in the epidermis), atypical lymphocytes with 'cerebriform' nuclei in the upper dermis and epidermis (plaque stage), or diffuse dermal lymphocyte infiltrate (tumor stage). See <bold>Image.</bold>&#x000a0;Pautrier Microabscesses. Lymphocytes may tag along the dermo-epidermal junction. Reactive, inflammatory skin changes (e.g., spongiosis) are typically absent.<xref ref-type="bibr" rid="article-150159.r28">[28]</xref>&#x000a0;The papillary dermis exhibits wiry collagen. IHC: CD3+, CD4+, CD5+/-, CD7-, CD25+/-, CD30+/-, CD56-, CCR4+.<xref ref-type="bibr" rid="article-150159.r29">[29]</xref></p>
        <p>MF Variants</p>
        <list list-type="bullet">
          <list-item>
            <p>FMF: Atypical lymphocyte infiltrate surrounding hair follicles (folliculotropism) with follicular mucinosis. Hair follicles may be intact, destructed, or have cysts with or without basaloid folliculolymphoid hyperplasia. It may be accompanied by eosinophils, granulomatous dermatitis, or perieccrine infiltrates (syringotropism).<xref ref-type="bibr" rid="article-150159.r30">[30]</xref><xref ref-type="bibr" rid="article-150159.r31">[31]</xref>&#x000a0;IHC: CD3+, CD4+, CD8-, with an elevated CD4:CD8 ratio (6-10:1); CD30 may be positive in large cell transformation.<xref ref-type="bibr" rid="article-150159.r31">[31]</xref><xref ref-type="bibr" rid="article-150159.r32">[32]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>PR: Epidermal atypical mononuclear (pagetoid) cell hyperplasia with eosinophilic cytoplasm. A dermal mixed inflammatory infiltrate with or without CD8+ epidermotropism may also be present. IHC: variable CD4, CD8, and CD30 expression; Ki-67/MIB1 may show active proliferation but is not specific.<xref ref-type="bibr" rid="article-150159.r33">[33]</xref><xref ref-type="bibr" rid="article-150159.r34">[34]</xref><xref ref-type="bibr" rid="article-150159.r35">[35]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>GSS: Diffuse loss of elastic fibers, non-caseating granulomatous T-cell infiltrates in the upper dermis, and multinucleated giant cells may all be present.<xref ref-type="bibr" rid="article-150159.r36">[36]</xref><xref ref-type="bibr" rid="article-150159.r37">[37]</xref>&#x000a0;IHC: CD4+/45RO+/30+; multinucleated giant cells, often CD68+, and may have surrounding CD1a+ cells.<xref ref-type="bibr" rid="article-150159.r38">[38]</xref><xref ref-type="bibr" rid="article-150159.r39">[39]</xref><xref ref-type="bibr" rid="article-150159.r40">[40]</xref></p>
          </list-item>
        </list>
        <p>ATL: Dermal tumor cell lymphocyte infiltrate with occasional epidermotropism. Patterns may vary from resembling MF to C-ALCL, or peripheral T-cell lymphoma, NOS.<xref ref-type="bibr" rid="article-150159.r29">[29]</xref><xref ref-type="bibr" rid="article-150159.r41">[41]</xref>&#x000a0;IHC: CD3+, CD5+, CD45RO+, CD8+/-, CD25+/-, CD30+/-, CD7-, CD20-, CD79a-; elevated Ki-67 may be present in more aggressive forms of ATL.<xref ref-type="bibr" rid="article-150159.r42">[42]</xref></p>
        <p>Primary cutaneous CD30+ lymphoproliferative disorders</p>
        <list list-type="bullet">
          <list-item>
            <p>C-ALCL: Large, irregular polygonal lymphocytes&#x000a0;in sheets throughout the dermis. Epidermotropism with or without subcutaneous or adnexal involvement may be present. Cutaneous lymphatic infiltration may be present. The "hallmark" feature of eosinophilic cells with horseshoe nuclei is not always present. IHC: CD30+ membranous and Golgi pattern expression in over 75% of tumor cells. Cytotoxic phenotype (i.e., CD8, TIA-1, granzyme, perforin) positivity may occur in angioinvasive cases.<xref ref-type="bibr" rid="article-150159.r2">[2]</xref><xref ref-type="bibr" rid="article-150159.r43">[43]</xref><xref ref-type="bibr" rid="article-150159.r44">[44]</xref></p>
          </list-item>
          <list-item>
            <p>LyP: (Type A) Wedge-shaped CD30+ tumor cells in scattered or clustered patterns with a mixed inflammatory infiltrate. (Type B) Epidermotropic CD30+/- tumor cells with cerebriform nuclei (resembling MF). (Type C) Sheets of large CD30+ atypical lymphoid cells with minimal reactive inflammatory cells. (Type D) Epidermotropic small- to medium-sized CD8+ and CD30+ tumor cells (resembling CD8+ AECTCL). (Type E) Large necrotic "eschar"-like lesions with angioinvasion secondary to CD8+ and CD30+ co-expressed atypical lymphocytes. IHC: CD3+, CD4+, CD25+, CD30+, CD45RO+, CD56+/-, CD2-, CD3-, CD5-, CD7-. CD8 positivity, as opposed to CD4, is more frequently seen in Type D and Type E.<xref ref-type="bibr" rid="article-150159.r2">[2]</xref><xref ref-type="bibr" rid="article-150159.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>SPTCL: Lobular panniculitis with atypical lymphocyte infiltrate. IHC: CD3+, CD4-, CD8+, CD56-, Ki-67+, cytotoxic granules+, EBER-ISH-.<xref ref-type="bibr" rid="article-150159.r29">[29]</xref></p>
        <p>Extranodal NK-cell/T-cell lymphoma, nasal type: Pleomorphic atypical lymphoid cells primarily limited to subcutis with angioinvasion and extensive connective tissue/blood vessel necrosis. IHC: CD3+, cytotoxic granules+, CD56+, CD43+/-, CD45RO+/-, CD4-, CD8-, CD16-, CD57-.<xref ref-type="bibr" rid="article-150159.r46">[46]</xref>&#x000a0;</p>
        <p>CAEBV infection: Cutaneous and subcutaneous adipocyte necrosis with septal atypical lymphocyte infiltrate; Reed Sternberg-like cells may be present in an NK-cell variant.<xref ref-type="bibr" rid="article-150159.r47">[47]</xref>&#x000a0;IHC: EBV+ lymphocytes with EBER positive signaling (&#x0003e;100/HPF); atypical T-cells may express CD3, CD4, CD5, CD7, CD8, TIA-1, or GRB (negative for CD2, CD56); Ki-67 positivity may show active proliferation.<xref ref-type="bibr" rid="article-150159.r48">[48]</xref>&#x000a0;</p>
        <p>Primary cutaneous peripheral T-cell lymphoma, rare subtypes</p>
        <list list-type="bullet">
          <list-item>
            <p>PCGDTL (provisional): Atypical lymphocyte infiltrate in the dermis and subcutis with occasional epidermotropism. IHC: CD3+, CD4-, CD5-, CD8+/-, cytotoxic granules+; T cell receptor (TCR)-&#x003b3;&#x003b4;+ (TCR-&#x003b1;&#x003b2;-).<xref ref-type="bibr" rid="article-150159.r29">[29]</xref><xref ref-type="bibr" rid="article-150159.r49">[49]</xref><xref ref-type="bibr" rid="article-150159.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>CD8+ AECTCL (provisional): Marked CD8+ epidermotropism with diffuse dermal atypical lymphocyte infiltrate. IHC: CD3+, CD4-, CD5-, CD8+, CD30-, cytotoxic granules+, EBER-ISH-.<xref ref-type="bibr" rid="article-150159.r29">[29]</xref><xref ref-type="bibr" rid="article-150159.r49">[49]</xref><xref ref-type="bibr" rid="article-150159.r29">[29]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>CD4+ SMT-LPD (provisional): Nodular to diffuse atypical dermal lymphocytes without epidermotropism and surrounded by a mixed inflammatory infiltrate. IHC: CD3+, CD4+, PD-1+, BCL6+, CXCL3+, CD8-, cytotoxic granules-.<xref ref-type="bibr" rid="article-150159.r29">[29]</xref><xref ref-type="bibr" rid="article-150159.r49">[49]</xref><xref ref-type="bibr" rid="article-150159.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Primary cutaneous acral CD8+ T-cell lymphoma (provisional): Diffuse dermal atypical lymphocyte infiltrate without epidermotropism. IHC: CD3+, CD8+, CD4-, CD30-, CD56-, TIA-1+, EBER-ISH-.<xref ref-type="bibr" rid="article-150159.r29">[29]</xref><xref ref-type="bibr" rid="article-150159.r49">[49]</xref><xref ref-type="bibr" rid="article-150159.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Primary cutaneous peripheral T-cell lymphoma, NOS: Remaining aggressive T-cell lymphoproliferative histologic entities which do not fit other established CTCL categories (namely CD4+ SMT-LPD, CD8+ AECTCL, and PCGDTL).<xref ref-type="bibr" rid="article-150159.r49">[49]</xref><xref ref-type="bibr" rid="article-150159.r50">[50]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Cutaneous B-cell&#x000a0;Lymphoma</bold>
</p>
        <p>PCMZL: Nodular or diffuse dermal lymphoplasmacytoid or monocytoid marginal zone B-cells with or without T-cells. Lymphoid follicles may be present. IHC: CD20+, CD79a+, BCL2+, BCL6-, CD5-, CD10-, CD16-.<xref ref-type="bibr" rid="article-150159.r29">[29]</xref><xref ref-type="bibr" rid="article-150159.r49">[49]</xref>&#x000a0;See<bold> Image.</bold> Dermal Plasma Cells.</p>
        <p>PCFCL: Dense proliferation of neoplastic follicular central B-cells ("centrocytes") separated from the epidermis by Grenz zone and exhibit background dendritic meshwork. The Ki-67 proliferation index is low. It may have surrounding reactive T-cells. IHC: CD19+, CD20+, CD22+, CD79a+, PAX5+, BCL6+, CD10+/-, BCL2-.<xref ref-type="bibr" rid="article-150159.r51">[51]</xref></p>
        <p>PCDLBLC, LT: Diffuse dermal sheets of monomorphic large B-cells with open chromatin and prominent nucleoli. The proliferation lacks background dendritic meshwork and shows a high proliferation index. IHC: CD19+, CD20+, CD22+, CD79a+, PAX-5+, BCL2+, IRF4/MUM-1+, FOXP1+.<xref ref-type="bibr" rid="article-150159.r52">[52]</xref>&#x000a0;</p>
        <p>EBVMCU (provisional): EBV+ atypical large B-cells resemble the appearance of DLBCL and classic Hodgkin lymphoma. A mixed inflammatory infiltrate may be present. Reactive T-cells may surround B-cell clusters. IHC: CD15+, CD30+, CD19+, CD22+, CD79a+, PAX-5+, EBV+, IRF4/MUM-1+, CD20+/-, CD10-, BCL6-.<xref ref-type="bibr" rid="article-150159.r2">[2]</xref>&#x000a0;</p>
        <p>IVBCL: Large atypical B-cells with large nuclei and varying nucleoli demonstrating intravascular proliferation/destruction. IHC: CD79a+, CD20+, IRF4/MUM-1+, CD5+/-, CD10+/- , CD29-, CD54-.<xref ref-type="bibr" rid="article-150159.r53">[53]</xref></p>
      </sec>
      <sec id="article-150159.s6" sec-type="Clinical Pathology">
        <title>Clinical Pathology</title>
        <p>T- and B-cell clonality studies are necessary ancillary tests to support the diagnosis of CTCL and CBCL, respectively, especially when distinguishing hyperplasia from monoclonality.&#x000a0;The use of primers against gene targets such as <italic toggle="yes">IGH</italic>, <italic toggle="yes">IGK</italic>, <italic toggle="yes">IGL</italic>, <italic toggle="yes">TRG</italic>, and <italic toggle="yes">TRB</italic> is up to 90% sensitive&#x000a0;in detecting most types of CL. However, these tests must be used alongside clinical, histologic, morphologic, and immunophenotypic data.</p>
        <p>Clinical following may be indicated in certain patients whose clinical and anatomic pathologic findings do not correlate initially with cutaneous lymphoma.&#x000a0;Dermatopathologists may ask for new samples from skin biopsies of different lesion sites when uncertain. Linking results of gene rearrangements in skin biopsies with results of peripheral blood samples may increase the reliability of these tests as well.<xref ref-type="bibr" rid="article-150159.r54">[54]</xref></p>
        <p>Although circulating atypical S&#x000e9;zary cells may be found in cases of MF, peripheral blood smear evaluation is necessary for patients with suspected SS (e.g., older-aged, erythrodermic, lymphadenopathy, generalized pruritus).<xref ref-type="bibr" rid="article-150159.r55">[55]</xref>&#x000a0;Furthermore, biomarker positivity for PD1 (CD279) and KIRLD2 (CD158k) can provide additional data that me help in differentiating SS from other erythrodermic inflammatory dermatoses in the skin and peripheral blood.<xref ref-type="bibr" rid="article-150159.r2">[2]</xref><xref ref-type="bibr" rid="article-150159.r56">[56]</xref><xref ref-type="bibr" rid="article-150159.r57">[57]</xref>&#x000a0;</p>
        <p>Alongside establishing definitive atypical, neoplastic T-cell monoclonal populations in the skin and blood, an absolute S&#x000e9;zary cell count of &#x0003e;1000/microliter in the peripheral blood with expanded CD4+ T cell population resulting in a CD4/CD8 ratio &#x02265; 10, CD4+/CD7- cells &#x02265; 30%, or CD4+/CD26&#x02212; cells &#x02265; 40% is necessary to establish a diagnosis of SS, according to the 2018 WHO-EORTC.<xref ref-type="bibr" rid="article-150159.r2">[2]</xref></p>
        <p>In patients with suspected ATL, peripheral blood smear showing &#x0201c;flower&#x0201d; or &#x0201c;cloverleaf&#x0201d; cells (polylobated T-cells with condensed chromatin) is pathognomonic. HTLV-1 infection should be confirmed by ELISA (highest sensitivity), western blot, or PCR. Recommended cytologic panel evaluation includes CD3, CD4, CD5, CD7, CD8, CD25, and CD30.<xref ref-type="bibr" rid="article-150159.r58">[58]</xref><xref ref-type="bibr" rid="article-150159.r59">[59]</xref><xref ref-type="bibr" rid="article-150159.r58">[58]</xref>&#x000a0;Patients with EBV-associated CL (e.g., CAEBV infection, EBVMCU, extranodal NK-cell/T-cell lymphoma, nasal type) require confirmation of viral infection for definitive diagnoses as well.<xref ref-type="bibr" rid="article-150159.r60">[60]</xref></p>
        <p>In patients with CBCL and lymphocytosis, peripheral blood flow cytometry is recommended, as well as bone marrow biopsy for those with disseminated skin disease or lymphadenopathy. In any patient with PCDLBCL-LT, both peripheral blood flow cytometry and bone marrow biopsy are recommended, given this condition&#x02019;s poor prognosis compared to other CBCL sub-types (5-year survival of about 50%).<xref ref-type="bibr" rid="article-150159.r49">[49]</xref></p>
      </sec>
      <sec id="article-150159.s7" sec-type="Biochemical and Genetic Pathology">
        <title>Biochemical and Genetic Pathology</title>
        <p>Although monoclonality by molecular analysis may help diagnose cutaneous lymphoma, its presence does not necessarily mean a malignancy, nor does its absence rule it out.<xref ref-type="bibr" rid="article-150159.r27">[27]</xref>&#x000a0;Analysis of antigen receptor genes (ARG) via rearrangement studies, such as IGH, are functional assays to help determine and distinguish CL from other lymphoproliferative entities.<xref ref-type="bibr" rid="article-150159.r61">[61]</xref>&#x000a0;</p>
        <p>Targeting mutations in genes involved in the MYC, BCL6, NF-&#x003ba;B, and&#x000a0;JAK-STAT signaling pathways, among others, may assist and serve as critical ancillary tests when working-up CTCL and CBCL.<xref ref-type="bibr" rid="article-150159.r2">[2]</xref><xref ref-type="bibr" rid="article-150159.r62">[62]</xref>&#x000a0;Several notable markers&#x000a0;are mentioned in this chapter's "Clinical Pathology" section. This aspect of CL evaluation is continually evolving as more research&#x000a0;is carried out to understand the underlying etiologies.</p>
      </sec>
      <sec id="article-150159.s8" sec-type="Clinicopathologic Correlations">
        <title>Clinicopathologic Correlations</title>
        <p>Clinicopathology correlation is essential when establishing a cutaneous lymphoma subtype diagnosis since most CLs demonstrate similar histology and immunophenotypes.<xref ref-type="bibr" rid="article-150159.r27">[27]</xref></p>
        <p>
<bold>Cutaneous T-cell&#x000a0;Lymphoma</bold>
</p>
        <p>MF: Presents as erythematous patches, plaques, tumors, or erythrodermic &#x0201c;stages,&#x0201d; most frequently involving non-sun-exposed &#x0201c;bathing suit&#x0201d; areas in older individuals. Lesions may accompany epidermal atrophy, scaling, or pruritis. Hypo- or hyper-pigmented patches/plaques may both be seen, especially in patients with skin of color. It rarely presents in children or adolescents (MF variants are more common in this population).<xref ref-type="bibr" rid="article-150159.r63">[63]</xref><xref ref-type="bibr" rid="article-150159.r64">[64]</xref></p>
        <p>MF Variants</p>
        <list list-type="bullet">
          <list-item>
            <p>FMF: Presents as grouped erythematous patches, plaques, and tumors accentuated around follicles on the neck and face (especially eyebrows). Patients often have alopecia (up to 81%), comedones, or rosacea-like skin changes. Although the mean age of onset is from 46 to 59 years old (in men more than women), FMF is a common variant of juvenile MF.<xref ref-type="bibr" rid="article-150159.r65">[65]</xref></p>
          </list-item>
          <list-item>
            <p>PR: Localized PR, also known as Woringer-Klopp disease (WKD), presents as solitary, hyperkeratotic verrucous, or psoriasiform plaques on the extremities of patients between their third and sixth decades of life. Like FMF, PR may show in pediatric individuals.<xref ref-type="bibr" rid="article-150159.r34">[34]</xref><xref ref-type="bibr" rid="article-150159.r66">[66]</xref>&#x000a0;Widespread PR is referred to as Ketron-Goodman disease and is more aggressive. Ketron-Goodman disease and metastatic PR are more challenging to treat and have higher mortality rates.<xref ref-type="bibr" rid="article-150159.r67">[67]</xref><xref ref-type="bibr" rid="article-150159.r68">[68]</xref></p>
          </list-item>
          <list-item>
            <p>GSS: Presents as erythematous, pruritic lax skin and wrinkles, mainly in flexure/axillary regions in men during their third to fourth decades of life. Plaques may be violaceous with atrophy and have mild desquamation.<xref ref-type="bibr" rid="article-150159.r36">[36]</xref><xref ref-type="bibr" rid="article-150159.r37">[37]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>SS: Presents more frequently in older persons as generalized erythroderma (i.e., greater than 80% body surface area) with exfoliation, edema, pruritus, or lichenification. Lymphadenopathy is common.<xref ref-type="bibr" rid="article-150159.r9">[9]</xref>&#x000a0;Skin classification, stage of disease, elevated LDH, advanced age, comorbidities, race, male sex, peripheral eosinophilia, and large cell transformation are all associated with a worse prognosis.<xref ref-type="bibr" rid="article-150159.r69">[69]</xref></p>
        <p>ATL: Presents as large, rapidly growing cutaneous papules, nodules, or tumors.<xref ref-type="bibr" rid="article-150159.r70">[70]</xref>&#x000a0;ATL is caused by HTLV-1, which affects around 10 million people worldwide annually. It is endemic in the north and south of Japan, the Caribbeans, Africa, the Middle East, South America, and Central America. Rapidly progressive disease is associated with chemotherapeutic resistance, immunosuppression, and an overall poor prognosis.<xref ref-type="bibr" rid="article-150159.r71">[71]</xref><xref ref-type="bibr" rid="article-150159.r72">[72]</xref><xref ref-type="bibr" rid="article-150159.r73">[73]</xref></p>
        <p>Primary cutaneous CD30+ lymphoproliferative disorders</p>
        <list list-type="bullet">
          <list-item>
            <p>C-ALCL: Presents as solitary, grouped, or multifocal (approximately 20% of the time) nodules or tumors that often persist for at least 3 to 4 weeks. Superficial ulceration may be present and frequently involves the extremities and face (less commonly the trunk). Cutaneous relapse may occur, and partial or complete regression happens in about 25% of patients. Most commonly, C-ALCL&#x000a0;arises&#x000a0;in patients between 50 to 70 years old but may occur in some pediatric populations.<xref ref-type="bibr" rid="article-150159.r43">[43]</xref><xref ref-type="bibr" rid="article-150159.r74">[74]</xref>&#x000a0;Leg, extensive skin, muscle, and deep fascia involvement all correlate with a&#x000a0;poorer prognosis.<xref ref-type="bibr" rid="article-150159.r75">[75]</xref><xref ref-type="bibr" rid="article-150159.r76">[76]</xref><xref ref-type="bibr" rid="article-150159.r77">[77]</xref></p>
          </list-item>
          <list-item>
            <p>LyP: Presents as a benign, chronic, and often relapsing papulonodular eruption over the face, trunk, or limbs. Post-inflammatory hypopigmented macules and atrophic scars in sites of spontaneous resolution may occur.<xref ref-type="bibr" rid="article-150159.r45">[45]</xref>&#x000a0;Older age and T-cell monoclonality are significant risk factors for secondary disease/cutaneous lymphoid malignancies (such as MF, C-ALCL, and Hodgkin lymphoma).<xref ref-type="bibr" rid="article-150159.r78">[78]</xref><xref ref-type="bibr" rid="article-150159.r79">[79]</xref><xref ref-type="bibr" rid="article-150159.r78">[78]</xref></p>
          </list-item>
        </list>
        <p>SPTCL: Often presents as multiple, relapsing, self-healing subcutaneous nodules on the trunk or extremities. Nodules are painless and may appear in the same or different skin locations. About 75% of patients have multifocal skin involvement. Associations of SPTCL include serosal effusions, hemophagocytosis, and pancytopenia.<xref ref-type="bibr" rid="article-150159.r80">[80]</xref></p>
        <p>Extranodal NK-cell/T-cell lymphoma, nasal type: Often presents as ulcerating, necrotizing, or destructive lesions on the midface, nose, or upper airways. Surrounding edema and erythema&#x000a0;may frequently occur. It is most common in Asia and Latin American geographic regions and among similar heritage groups. Positive EBV detection via in situ hybridization (ISH) is necessary to confirm the diagnosis.<xref ref-type="bibr" rid="article-150159.r46">[46]</xref></p>
        <p>CAEBV infection: According to the 2018 WHO-EORTC, this diagnosis includes EBV+ lymphoproliferative disorders (LPD) in childhood, which has two sub-classifications: hydroa vacciniform-like LPD (HV-like LPD) and severe mosquito bite allergy (sMBA).<xref ref-type="bibr" rid="article-150159.r81">[81]</xref><xref ref-type="bibr" rid="article-150159.r82">[82]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>HV-like LPD: Presents as a papulovesicular eruption on sun-exposed skin areas (e.g., face, ear lobes, back of hands) with or without systemic symptoms (e.g., fever, lymphadenopathy). Extensive non-sun-exposed skin involvement, facial swelling, and extensive ulcers may suggest the severity of the disease.</p>
          </list-item>
          <list-item>
            <p>sMBA: Presents as ulceronecrotic lesions at the site of mosquito bites with similar systemic symptoms as seen in patients with HV-like LPD. This condition is most common in children and young adults, and patients of Asian or Hispanic descent.</p>
          </list-item>
        </list>
        <p>Primary cutaneous peripheral T-cell lymphoma, rare subtypes</p>
        <list list-type="bullet">
          <list-item>
            <p>PCGDTL (provisional): May present as diffuse superficial patches and plaques on the extremities with or without facial tumor ulceration. Lesions may appear similar to Pyoderma gangrenosum on the legs, deep nodules on the trunk, or in conjunction with MF-like plaques on non-sun-exposed skin areas. It is more likely to present in adults aged 40 to 70 and has a poor prognosis.<xref ref-type="bibr" rid="article-150159.r83">[83]</xref></p>
          </list-item>
          <list-item>
            <p>CD8+ AECTCL (provisional): May present as Pyoderma gangrenosum-like lesions or PR-like patches and plaques with hyperkeratosis. Lesions may appear as annular or erythematous widespread papules, plaques, and ulcerated tumors without precursor lesions. They tend to appear suddenly and rapidly within weeks to months and may be locally aggressive. They occur most commonly on acral skin surfaces; oral involvement indicates a poor prognosis. The age of presentation is broad, from young adults to the elderly.<xref ref-type="bibr" rid="article-150159.r84">[84]</xref></p>
          </list-item>
          <list-item>
            <p>CD4+SMT-LPD (provisional): Commonly presents as asymptomatic, solitary, slow-growing violaceous or erythematous papules, plaques, nodules, or tumors. Most cases involve the head and neck, followed by the trunk and upper extremities. Pain or pruritus may occur, but ulceration is rare. Although these occur predominately in elderly persons in the sixth and seventh decades of life, pediatric patients may also be affected.<xref ref-type="bibr" rid="article-150159.r85">[85]</xref></p>
          </list-item>
          <list-item>
            <p>Primary cutaneous acral CD8+ T-cell lymphoma (provisional): Presents most commonly in adult males older than 50 as solitary, slow-growing nodules on the ear, although they may occur on the nose, hands, and feet. Symmetric skin involvement is not uncommon, and this disease exhibits an indolent course.<xref ref-type="bibr" rid="article-150159.r86">[86]</xref></p>
          </list-item>
          <list-item>
            <p>Primary cutaneous peripheral T-cell lymphoma, NOS: May present as solitary erythematous to violaceous tumors or nodules throughout the body. Ulceration and subsequent infection may occur, and rapid dissemination with systemic symptoms is not uncommon. The prognosis is abysmal, with a five-year disease survival rate of less than 20%, and is more likely to appear in older adults/elderly persons.<xref ref-type="bibr" rid="article-150159.r50">[50]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Cutaneous B-cell&#x000a0;Lymphoma</bold>
</p>
        <p>PCMZL: Typically presents as pink, red, or violaceous papules, plaques, or nodules. They commonly occur on the arms or trunk instead of the head and neck and predominately appear in adult males 50 to 60. However, they frequently appear as rare cases of CL among children and adolescents.<xref ref-type="bibr" rid="article-150159.r87">[87]</xref></p>
        <p>PCFCL: Presents as one or more localized, erythematous papules, plaques, or tumors on the scalp, forehead, or trunk of adult males 50 to 60 years old.<xref ref-type="bibr" rid="article-150159.r51">[51]</xref>&#x000a0;</p>
        <p>PCDLBLC, LT: Often presents as rapidly developing red to plum nodules or tumors on one or both legs of older women (median age of diagnosis is 70 years old). This condition frequently spreads to extracutaneous sites, namely lymph nodes and bone marrow, and warrants further hematopathology evaluation due to its poor prognosis.<xref ref-type="bibr" rid="article-150159.r52">[52]</xref>&#x000a0;</p>
        <p>EBVMCU (provisional): Appears as shallow, well-circumscribed mucosal or cutaneous ulcers with indolent disease progression. Most patients experience spontaneous regression. The median patient age upon presentation is around 66 years old, with a slight female predominance.<xref ref-type="bibr" rid="article-150159.r88">[88]</xref></p>
        <p>IVBCL: A rare subtype of DLBCL with intravascular involvement leading to blood vessel destruction and necrosis. Lesions may present anywhere in the body, but skin involvement is more common in persons of Western populations. Constitutional B symptoms may also occur. Disseminated disease most commonly affects elderly persons around 70 years old without gender predilection.<xref ref-type="bibr" rid="article-150159.r53">[53]</xref></p>
      </sec>
      <sec id="article-150159.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>In light of discussions from the 2021 Clinical Advisory Committee (CAC) and recognition of updated WHO guidelines, the 2022 International Consensus Classification (ICC) of lymphomas continues to acknowledge the frequent evolution of CL subtype classification.</p>
        <p>Clinically, accurate diagnosis of which cutaneous lymphoma subtype is present is essential as different entities have varying expected behavioral patterns and prognostic implications. Practitioners should understand that many CL subtypes have overlapping histopathologic features, which is significant as dermatopathologists rely heavily on the presentation and features of clinical lesions (i.e., clinicopathologic correlation) to determine the most accurate CL subtype diagnosis for each patient.</p>
        <p>Although a&#x000a0;complete understanding of CL is yet to be determined, continued collaborative extensive cohort studies and advances in biomolecular detective technology (i.e., genetic, epigenetic) may&#x000a0;help dermatopathologists, dermatologists, and other practitioners in characterizing and further subclassifying these various entities to provide outstanding patient care.<xref ref-type="bibr" rid="article-150159.r89">[89]</xref></p>
      </sec>
      <sec id="article-150159.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=150159&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=150159">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/150159/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=150159">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-150159.s11">
        <fig id="article-150159.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Dermal B-Cell Infiltrate (CBCL) Used with permission from PathPresenter</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2022-11-04__at__9.22.18__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-150159.s12">
        <fig id="article-150159.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Epidermotropism (CTCL) Used with permission from PathPresenter</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2022-11-04__at__9.24.43__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-150159.s13">
        <fig id="article-150159.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Pautrier Microabscesses Used with permission from PathPresenter</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2022-11-04__at__9.28.59__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-150159.s14">
        <fig id="article-150159.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Dense B-Cell Dermal Infiltrate (CBCL) Used with permission from PathPresenter</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2022-11-04__at__9.30.34__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-150159.s15">
        <fig id="article-150159.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Dermal Plasma Cells Used with permission from PathPresenter</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2022-11-04__at__9.33.32__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-150159.s16">
        <title>References</title>
        <ref id="article-150159.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mitteldorf</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous lymphomas-An update 2019.</article-title>
            <source>Hematol Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>37 Suppl 1</volume>
            <fpage>43</fpage>
            <page-range>43-47</page-range>
            <pub-id pub-id-type="pmid">31187534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Facchetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Apr</month>
            <day>18</day>
            <volume>133</volume>
            <issue>16</issue>
            <fpage>1703</fpage>
            <page-range>1703-1714</page-range>
            <pub-id pub-id-type="pmid">30635287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Skov</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous Lymphomas.</article-title>
            <source>Clin Oncol (R Coll Radiol)</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>797</fpage>
            <page-range>797-807</page-range>
            <pub-id pub-id-type="pmid">31405542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ralfkiaer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chimenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diaz-Perez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kerl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurrer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sterry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>WHO-EORTC classification for cutaneous lymphomas.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>May</month>
            <day>15</day>
            <volume>105</volume>
            <issue>10</issue>
            <fpage>3768</fpage>
            <page-range>3768-85</page-range>
            <pub-id pub-id-type="pmid">15692063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Criscione</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.</article-title>
            <source>Arch Dermatol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>143</volume>
            <issue>7</issue>
            <fpage>854</fpage>
            <page-range>854-9</page-range>
            <pub-id pub-id-type="pmid">17638728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agar</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Wedgeworth</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crichton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calonje</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stefanato</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wain</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scarisbrick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Survival outcomes and prognostic factors in mycosis fungoides/S&#x000e9;zary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Nov</month>
            <day>01</day>
            <volume>28</volume>
            <issue>31</issue>
            <fpage>4730</fpage>
            <page-range>4730-9</page-range>
            <pub-id pub-id-type="pmid">20855822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wohlmuth-Wieser</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous T-cell lymphomas in childhood and adolescence.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>563</fpage>
            <page-range>563-581</page-range>
            <pub-id pub-id-type="pmid">33861015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Leary</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janakiram</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>85</volume>
            <issue>6</issue>
            <fpage>1418</fpage>
            <page-range>1418-1428</page-range>
            <pub-id pub-id-type="pmid">32822803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larocca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kupper</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Mycosis Fungoides and S&#x000e9;zary Syndrome: An Update.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-120</page-range>
            <pub-id pub-id-type="pmid">30497668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsen</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.</article-title>
            <source>Dermatol Clin</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>643</fpage>
            <page-range>643-54</page-range>
            <pub-id pub-id-type="pmid">26433839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oschlies</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wehkamp</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous B cell lymphomas: standards in diagnostic and clinical work-up. Hints, pitfalls and recent advances.</article-title>
            <source>Histopathology</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>184</fpage>
            <page-range>184-195</page-range>
            <pub-id pub-id-type="pmid">34958501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molloy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jonak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Woei-A-Jin</surname>
                <given-names>FJSH</given-names>
              </name>
              <name>
                <surname>Guenova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Busschots</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bervoets</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hauben</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porkert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fassnacht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Papadavid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alberti Violetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Estrach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akilov</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vakeva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bayne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wachsmuch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wehkamp</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Marschalko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Servitje</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weatherhead</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wobser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanches</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klemke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Howles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Evison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scarisbrick</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Characteristics associated with significantly worse quality of life in mycosis fungoides/S&#x000e9;zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.</article-title>
            <source>Br J Dermatol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>182</volume>
            <issue>3</issue>
            <fpage>770</fpage>
            <page-range>770-779</page-range>
            <pub-id pub-id-type="pmid">31049926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhat</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Herbosa</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Sogade</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jeffe</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Mehta-Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Semenov</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Musiek</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.</article-title>
            <source>Br J Dermatol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>184</volume>
            <issue>2</issue>
            <fpage>310</fpage>
            <page-range>310-318</page-range>
            <pub-id pub-id-type="pmid">32510571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porkert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oerlemans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papadavid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Molloy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lehner-Baumgartner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cozzio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Efficace</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scarisbrick</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>99</volume>
            <issue>7</issue>
            <fpage>640</fpage>
            <page-range>640-646</page-range>
            <pub-id pub-id-type="pmid">30868169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elenitoba-Johnson</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A new molecular paradigm in mycosis fungoides and S&#x000e9;zary syndrome.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">28024703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Degasperi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grandi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Amarante</surname>
                <given-names>TD</given-names>
              </name>
              <collab>Genomics England Research Consortium</collab>
              <name>
                <surname>Mitchell</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Nik-Zainal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Feb</month>
            <day>17</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>3962</fpage>
            <pub-id pub-id-type="pmid">33597573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wartewig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ringbloom</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Martinez-Escala</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Doukas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Snowden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Conran</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tegtmeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Pease</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Jothishankar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Abdulla</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Louissaint</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boggon</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Sosman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guitart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ruland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.</article-title>
            <source>Blood</source>
            <year>2021</year>
            <month>Oct</month>
            <day>07</day>
            <volume>138</volume>
            <issue>14</issue>
            <fpage>1225</fpage>
            <page-range>1225-1236</page-range>
            <pub-id pub-id-type="pmid">34115827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyashiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sanches</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of adult T-cell leukemia/lymphoma.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-91</page-range>
            <pub-id pub-id-type="pmid">31387753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hristov</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Tejasvi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>A Wilcox</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>96</volume>
            <issue>10</issue>
            <fpage>1313</fpage>
            <page-range>1313-1328</page-range>
            <pub-id pub-id-type="pmid">34297414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jahan-Tigh</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Huen</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Pozadzides</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series.</article-title>
            <source>Cancer</source>
            <year>2013</year>
            <month>Feb</month>
            <day>15</day>
            <volume>119</volume>
            <issue>4</issue>
            <fpage>825</fpage>
            <page-range>825-31</page-range>
            <pub-id pub-id-type="pmid">22952039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pease</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Martinez-Escala</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guitart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Nardone</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous T-cell lymphoma after chronic exposure to hydrochlorothiazide: pharmacovigilance analysis from the RADAR (Research on Adverse Drug events And Reports) Program.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>e106</fpage>
            <page-range>e106-e108</page-range>
            <pub-id pub-id-type="pmid">33480442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dumont</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Battistella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ram-Wolff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Masson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives.</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Jun</month>
            <day>08</day>
            <volume>12</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">32521744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bogle</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Riddle</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Triana</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous B-cell lymphoma.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>479</fpage>
            <page-range>479-84</page-range>
            <pub-id pub-id-type="pmid">16112357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mo</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>QR</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified, in a nonimmunocompromised young man: A case report.</article-title>
            <source>J Cutan Pathol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-389</page-range>
            <pub-id pub-id-type="pmid">31658378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Farisoglio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Calzavara Pinton</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report.</article-title>
            <source>Dermatology</source>
            <year>2007</year>
            <volume>215</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-32</page-range>
            <pub-id pub-id-type="pmid">17823520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vermeesch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lafond</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma: a rare and aggressive cutaneous lymphoma.</article-title>
            <source>Cutis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>102</volume>
            <issue>6</issue>
            <fpage>421</fpage>
            <page-range>421-424</page-range>
            <pub-id pub-id-type="pmid">30657800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mitteldorf</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pathologic Diagnosis of Cutaneous Lymphomas.</article-title>
            <source>Dermatol Clin</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>655</fpage>
            <page-range>655-81</page-range>
            <pub-id pub-id-type="pmid">26433840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsayyah</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Is it mycosis fungoides? A comprehensive guide to reaching the diagnosis and avoiding common pitfalls.</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>47</volume>
            <fpage>151546</fpage>
            <pub-id pub-id-type="pmid">32554312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyagaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and prognostic stratification of cutaneous lymphoma.</article-title>
            <source>J Dermatol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>210</fpage>
            <page-range>210-222</page-range>
            <pub-id pub-id-type="pmid">34346516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Se&#x000e7;kin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Demirkesen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baykal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000fc;y&#x000fc;kbabani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Two Clinically Unusual Cases of Folliculotropic Mycosis Fungoides: One with and the Other without Syringotropism.</article-title>
            <source>Ann Dermatol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>385</fpage>
            <page-range>385-91</page-range>
            <pub-id pub-id-type="pmid">24966641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerami</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guitart</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>1430</fpage>
            <page-range>1430-8</page-range>
            <pub-id pub-id-type="pmid">17721200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Folliculotropic Mycosis Fungoides With CD30+ Large-Cell Transformation.</article-title>
            <source>Am J Med Sci</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>356</volume>
            <issue>5</issue>
            <fpage>e37</fpage>
            <page-range>e37-e38</page-range>
            <pub-id pub-id-type="pmid">30205898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stahly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manway</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sukpraprut-Braaten</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pagetoid Reticulosis: A Rare Dermatologic Malignancy Presenting in a Middle-Aged Female.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e18524</fpage>
            <pub-id pub-id-type="pmid">34754679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haghighi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smoller</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>LeBoit</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Warnke</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study.</article-title>
            <source>Mod Pathol</source>
            <year>2000</year>
            <month>May</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>502</fpage>
            <page-range>502-10</page-range>
            <pub-id pub-id-type="pmid">10824921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas.</article-title>
            <source>J Cutan Pathol</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>465</fpage>
            <page-range>465-72</page-range>
            <pub-id pub-id-type="pmid">12207740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldsztajn</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Moritz Trope</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ribeiro Lenzi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Cuzzi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ramos-E-Silva</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Granulomatous slack skin. Histopathology diagnosis preceding clinical manifestations by 12 years.</article-title>
            <source>J Dermatol Case Rep</source>
            <year>2012</year>
            <month>Dec</month>
            <day>31</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>108</fpage>
            <page-range>108-12</page-range>
            <pub-id pub-id-type="pmid">23329989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Safaya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Granulomatous slack skin disease: a review, in comparison with mycosis fungoides.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>1472</fpage>
            <page-range>1472-8</page-range>
            <pub-id pub-id-type="pmid">22435618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ostheeren-Michaelis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paulli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucioni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Audring</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Assaf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>R&#x000fc;diger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hallermann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berneburg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chimenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marschalko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kazakov</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Petrella</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fraitag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carlotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Courville</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laeng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Golling</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <collab>Cutaneous Lymphoma Histopathology Task Force Group of the European Organization for Research and Treatment of Cancer</collab>
            </person-group>
            <article-title>Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC).</article-title>
            <source>Arch Dermatol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>144</volume>
            <issue>12</issue>
            <fpage>1609</fpage>
            <page-range>1609-17</page-range>
            <pub-id pub-id-type="pmid">19075143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cozzio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>S Jaffe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chimenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diaz-Perez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kazakov</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Kerl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurrer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ralfkiaer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Russell-Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sterry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.</article-title>
            <source>J Cutan Pathol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>647</fpage>
            <page-range>647-74</page-range>
            <pub-id pub-id-type="pmid">16293178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motta</surname>
                <given-names>LMD</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Nakandakari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>GVD</given-names>
              </name>
              <name>
                <surname>Nigro</surname>
                <given-names>MHMF</given-names>
              </name>
              <name>
                <surname>Brand&#x000e3;o</surname>
                <given-names>LSG</given-names>
              </name>
            </person-group>
            <article-title>Granulomatous slack skin: a rare subtype of mycosis fungoides.</article-title>
            <source>An Bras Dermatol</source>
            <year>2017</year>
            <season>Sep-Oct</season>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>694</fpage>
            <page-range>694-697</page-range>
            <pub-id pub-id-type="pmid">29166509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bittencourt</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Farr&#x000e9;</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases.</article-title>
            <source>Acta Oncol</source>
            <year>2009</year>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>598</fpage>
            <page-range>598-604</page-range>
            <pub-id pub-id-type="pmid">19165640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hasui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Matsuyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL.</article-title>
            <source>J Clin Exp Hematop</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">18434687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Fernandez-Pol</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous anaplastic large cell lymphoma.</article-title>
            <source>J Cutan Pathol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>570</fpage>
            <page-range>570-577</page-range>
            <pub-id pub-id-type="pmid">28342276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moodley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nombona</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mosam</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Primary Cutaneous Anaplastic Large-Cell Lymphoma.</article-title>
            <source>Dermatopathology (Basel)</source>
            <year>2019</year>
            <season>Apr-Jun</season>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-169</page-range>
            <pub-id pub-id-type="pmid">31700858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez-Cabriales</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shear</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Lymphomatoid papulosis: an update and review.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-73</page-range>
            <pub-id pub-id-type="pmid">31494989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez-Romero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bologna-Molina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paes de Almeida</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Santos-Silva</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Prado-Ribeiro</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Brand&#x000e3;o</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Carlos</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Extranodal NK/T cell lymphoma, nasal type: An updated overview.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>159</volume>
            <fpage>103237</fpage>
            <pub-id pub-id-type="pmid">33493634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With "Hodgkin/Reed-Sternberg-like" Cells of NK Phenotype.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1611</fpage>
            <page-range>1611-1621</page-range>
            <pub-id pub-id-type="pmid">31305266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Chronic Active Epstein-Barr Virus Infection With Subcutaneous Nodules and Systemic Damage.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>759834</fpage>
            <pub-id pub-id-type="pmid">35433738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubio-Gonzalez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Querfeld</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>176</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-36</page-range>
            <pub-id pub-id-type="pmid">27782301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aderhold</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma.</article-title>
            <source>Case Rep Oncol Med</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>429068</fpage>
            <pub-id pub-id-type="pmid">26380134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skala</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hristov</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hristov</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Primary Cutaneous Follicle Center Lymphoma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>142</volume>
            <issue>11</issue>
            <fpage>1313</fpage>
            <page-range>1313-1321</page-range>
            <pub-id pub-id-type="pmid">30407851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hristov</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous diffuse large B-cell lymphoma, leg type: diagnostic considerations.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>136</volume>
            <issue>8</issue>
            <fpage>876</fpage>
            <page-range>876-81</page-range>
            <pub-id pub-id-type="pmid">22849734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukherjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>IF</given-names>
              </name>
            </person-group>
            <article-title>Intravascular large B-cell lymphoma: an elusive diagnosis with challenging management.</article-title>
            <source>J Community Support Oncol</source>
            <year>2018</year>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>e280</fpage>
            <page-range>e280-e282</page-range>
            <pub-id pub-id-type="pmid">32984438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andea</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Guitart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Best practices in diagnostic immunohistochemistry: workup of cutaneous lymphoid lesions in the diagnosis of primary cutaneous lymphoma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>139</volume>
            <issue>3</issue>
            <fpage>338</fpage>
            <page-range>338-50</page-range>
            <pub-id pub-id-type="pmid">25724031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soko&#x00142;owska-Wojdy&#x00142;o</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olek-Hrab</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ruckemann-Dziurdzi&#x00144;ska</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous lymphomas: diagnosis and treatment.</article-title>
            <source>Postepy Dermatol Alergol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>368</fpage>
            <page-range>368-83</page-range>
            <pub-id pub-id-type="pmid">26759546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cetin&#x000f6;zman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Differential expression of programmed death-1 (PD-1) in S&#x000e9;zary syndrome and mycosis fungoides.</article-title>
            <source>Arch Dermatol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>148</volume>
            <issue>12</issue>
            <fpage>1379</fpage>
            <page-range>1379-85</page-range>
            <pub-id pub-id-type="pmid">23247480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hurabielle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thonnart</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ram-Wolff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sicard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bensussan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marie-Cardine</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with S&#x000e9;zary Syndrome.</article-title>
            <source>Clin Cancer Res</source>
            <year>2017</year>
            <month>Jul</month>
            <day>15</day>
            <volume>23</volume>
            <issue>14</issue>
            <fpage>3619</fpage>
            <page-range>3619-3627</page-range>
            <pub-id pub-id-type="pmid">28119365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Adult T-cell leukemia/lymphoma.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-8</page-range>
            <pub-id pub-id-type="pmid">24982574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Human T lymphotropic virus type-I and adult T-cell leukemia in Japan.</article-title>
            <source>Int J Hematol</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>76 Suppl 2</volume>
            <fpage>240</fpage>
            <page-range>240-5</page-range>
            <pub-id pub-id-type="pmid">12430931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gru</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous EBV-related lymphoproliferative disorders.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-75</page-range>
            <pub-id pub-id-type="pmid">27988064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raess</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Bagg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role of molecular pathology in the diagnosis of cutaneous lymphomas.</article-title>
            <source>Patholog Res Int</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>913523</fpage>
            <pub-id pub-id-type="pmid">23213624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damsky</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>33</fpage>
            <pub-id pub-id-type="pmid">27262707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Mycosis Fungoides in Children and Adolescents: A Systematic Review.</article-title>
            <source>JAMA Dermatol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>157</volume>
            <issue>4</issue>
            <fpage>431</fpage>
            <page-range>431-438</page-range>
            <pub-id pub-id-type="pmid">33656521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Sweren</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Mycosis fungoides in pediatric patients: Clinical features, diagnostic challenges, and advances in therapeutic management.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-28</page-range>
            <pub-id pub-id-type="pmid">31630432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitteldorf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Folliculotropic mycosis fungoides.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2018</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>543</fpage>
            <page-range>543-557</page-range>
            <pub-id pub-id-type="pmid">29726638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torre-Castro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carrasco Santos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Pinilla</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Requena</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pagetoid reticulosis in a 13-year old female. A unique immunohistochemical profile.</article-title>
            <source>J Cutan Pathol</source>
            <year>2020</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>466</fpage>
            <page-range>466-469</page-range>
            <pub-id pub-id-type="pmid">31785005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlesimo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tammaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fidanza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Narcisi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cacchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Camplone</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Case of Ketron-Goodman Disease.</article-title>
            <source>Case Rep Dermatol</source>
            <year>2009</year>
            <month>Sep</month>
            <day>12</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-43</page-range>
            <pub-id pub-id-type="pmid">20652112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilcox</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>86</volume>
            <issue>11</issue>
            <fpage>928</fpage>
            <page-range>928-48</page-range>
            <pub-id pub-id-type="pmid">21990092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Villasenor-Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary Management of Mycosis Fungoides/S&#x000e9;zary Syndrome.</article-title>
            <source>Curr Hematol Malig Rep</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-243</page-range>
            <pub-id pub-id-type="pmid">28540671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cook</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Fuji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tanase</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bumbea</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cwynarski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Waldmann</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marcais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sibon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lunning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Imaizumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uchimaru</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takaori-Kondo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tokura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>10</day>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>677</fpage>
            <page-range>677-687</page-range>
            <pub-id pub-id-type="pmid">30657736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.</article-title>
            <source>Adv Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-152</page-range>
            <pub-id pub-id-type="pmid">29411267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>DU</given-names>
              </name>
              <name>
                <surname>Proietti</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ara&#x000fa;jo</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Guedes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Carneiro-Proietti</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>577</fpage>
            <page-range>577-89</page-range>
            <pub-id pub-id-type="pmid">20610824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>How I treat adult T-cell leukemia/lymphoma.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Aug</month>
            <day>18</day>
            <volume>118</volume>
            <issue>7</issue>
            <fpage>1736</fpage>
            <page-range>1736-45</page-range>
            <pub-id pub-id-type="pmid">21673346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leventaki</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pathology and genetics of anaplastic large cell lymphoma.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-71</page-range>
            <pub-id pub-id-type="pmid">31882178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous anaplastic large-cell lymphoma (ALCL): A comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>1135</fpage>
            <page-range>1135-43</page-range>
            <pub-id pub-id-type="pmid">26897385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Franc&#x000e9;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charlotte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barrou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dereure</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Fatal outcome of deep-penetrating lower limb primary cutaneous anaplastic large cell lymphomas in two immunocompromised patients.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>627</fpage>
            <page-range>627-30</page-range>
            <pub-id pub-id-type="pmid">19997696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Izutsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takazawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohmatsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoshimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tamaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous anaplastic large cell lymphoma with leg involvement: a case report and review of 11 cases.</article-title>
            <source>J Dermatol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>1009</fpage>
            <page-range>1009-12</page-range>
            <pub-id pub-id-type="pmid">21434982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pfaltz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Cozzio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ortiz-Romero</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hodak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Guitart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Estrach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sanches</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ranki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dreno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ostheeren-Michaelis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Oct</month>
            <day>13</day>
            <volume>118</volume>
            <issue>15</issue>
            <fpage>4024</fpage>
            <page-range>4024-35</page-range>
            <pub-id pub-id-type="pmid">21841159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cordel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tressi&#x000e8;res</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D'Incan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Est&#x000e8;ve</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Dalac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ingen-Housz-Oro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <collab>French Study Group on Cutaneous Lymphoma</collab>
            </person-group>
            <article-title>Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.</article-title>
            <source>Oncologist</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-83</page-range>
            <pub-id pub-id-type="pmid">26668250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugeeth</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jayasudha</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Subcutaneous panniculitis-like T-cell lymphoma.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-77</page-range>
            <pub-id pub-id-type="pmid">28127142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chronic Active Epstein-Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods.</article-title>
            <source>Microorganisms</source>
            <year>2021</year>
            <month>Jan</month>
            <day>15</day>
            <volume>9</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33467742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandez-Pol</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Natkunam</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Defining the elusive boundaries of chronic active Epstein-Barr virus infection.</article-title>
            <source>Haematologica</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>924</fpage>
            <page-range>924-927</page-range>
            <pub-id pub-id-type="pmid">29866887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alberti-Violetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maronese</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Venegoni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merlo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Primary Cutaneous Gamma-Delta T Cell Lymphomas: A Case Series and Overview of the Literature.</article-title>
            <source>Dermatopathology (Basel)</source>
            <year>2021</year>
            <month>Nov</month>
            <day>17</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>515</fpage>
            <page-range>515-524</page-range>
            <pub-id pub-id-type="pmid">34842638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nofal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdel-Mawla</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Assaf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salah</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>748</fpage>
            <page-range>748-59</page-range>
            <pub-id pub-id-type="pmid">22226429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gru</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wick</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Eid</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder-clinical and histopathologic features, differential diagnosis, and treatment.</article-title>
            <source>Semin Cutan Med Surg</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-48</page-range>
            <pub-id pub-id-type="pmid">29719019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hathuc</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Hristov</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Primary Cutaneous Acral CD8<sup>+</sup> T-Cell Lymphoma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>141</volume>
            <issue>11</issue>
            <fpage>1469</fpage>
            <page-range>1469-1475</page-range>
            <pub-id pub-id-type="pmid">29072952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous marginal zone lymphomas.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-84</page-range>
            <pub-id pub-id-type="pmid">27986434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gion</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A review of EBV-positive mucocutaneous ulcers focusing on clinical and pathological aspects.</article-title>
            <source>J Clin Exp Hematop</source>
            <year>2019</year>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>64</fpage>
            <page-range>64-71</page-range>
            <pub-id pub-id-type="pmid">31257347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150159.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodlad</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in cutaneous lymphoma-implications for current and future classifications.</article-title>
            <source>Virchows Arch</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>482</volume>
            <issue>1</issue>
            <fpage>281</fpage>
            <page-range>281-298</page-range>
            <pub-id pub-id-type="pmid">36278991</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
